Covidien announced on 26 December 2012 a definitive agreement to acquire CV Ingenuity.The companies expect to complete the acquisition in the first quarter of 2013. Financial terms of the transaction were not disclosed.
Covidien ($COV) has wrapped up its acquisition of startup CV Ingenuity, snagging the rights to the company s in-development drug-coated balloon designed to treat peripheral artery disease. The financial terms remain closely kept, but Covidien has said it will increase R&D spending by $20 million in the second half of fiscal 2013, and much of that cash will go into polishing up CV s rapid-release balloon for a regulatory debut.
Sumaria Macdonald, Freeman Hospital, Newcastle, UK, in a presentation at the British Society of Interventional Radiology s (BSIR) Annual Meeting (14–16 November, Bournemouth, UK) told delegates that drug-eluting stents ease severe pain when walking in patients with peripheral vascular disease.
Covidien announced the five-year results of the ClosureFast Long-Term European Multi-Center Study in patients with chronic venous insufficiency in December. The ClosureFast study was conducted prospectively at eight centres in Europe. The Venefit procedure (using the ClosureFast radiofrequency ablation catheter) was used to treat 295 lower limbs in 225 patients diagnosed with superficial venous reflux, the underlying cause of varicose veins and chronic venous insufficiency.
By Nicolas Diehm. Endovascular therapy has matured to be the primary revascularisation strategy for about 90% of patients with peripheral arterial disease (EVEM panel data Q2/2012). Ever since the first percutaneous transluminal angioplasty carried out in Switzerland in 1977, restenosis remains a major drawback of endovascular therapy. Numerous attempts to improve patency after balloon angioplasty including drug treatment approaches, endovascular brachytherapy, bare metal nitinol stents and paclitaxel-coated nitniol stents have been investigated.
Krassi Ivancev, University College and Royal Free Hospital, London, UK, presented at the VEITHsymposium (14-18 November 2012, New York, USA) the experience of complete endovascular graft exclusion of arch aneurysms using a non-custom-made branched arched device.
Flexible Stenting Solutions (FFS) announced on 21 December 2012 that it has received the CE mark and is now authorised to market its 6F reconstrainable FlexStent self-expanding stent system in the European Union. FSS is a developer of next-generation peripheral, neurovascular and biliary stents. This new device combines the advanced FlexStent technology with unique reconstrainable stent delivery technology, the company said.
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today introduced GORE® DrySeal Sheath with hydrophilic coating, allowing for easier insertion and removal to and from blood vessels during endovascular repair procedures. The device is designed to increase sheath lubricity with an advantage of minimizing particulation of the hydrophilic coating.
According to results from the PACIFIER (Paclitaxel-coated balloons in femoral indication to defeat restenosis) trial, led by Michael Werk, Martin Luther Hospital, Berlin, Germany, and published in Circulation: Cardiovascular Interventions, percutaneous transluminal angioplasty (PTA) with drug-eluting balloons (DEBs) is associated with significant reductions in late lumen loss and restenosis compared with angioplasty with uncoated balloons in patients with femoropopliteal artery disease.
According to results from the PACIFIER (Paclitaxel-coated balloons in femoral indication to defeat restenosis) trial, led by Michael Werk, Martin Luther Hospital, Berlin, Germany, and published in Circulation: Cardiovascular Interventions, percutaneous transluminal angioplasty (PTA) with drug-eluting balloons (DEBs) is associated with significant reductions in late lumen loss and restenosis compared with angioplasty with uncoated balloons in patients with femoropopliteal artery disease.
According to a quality of life sub-analysis from the DREAM trial, endovascular aneurysm repair (EVAR) shows a moderate benefit of quality of life up to six weeks after the procedure but open repair wins in the long run. The results were presented by Jan D Blankensteijn, associate professor of surgery, VU Medical Center, Amsterdam, The Netherlands, at the VEITHsymposium (14–18 November, New York, USA).
By Roberto Sacilotto. In the past decade, the most significant change in the treatment of critical limb ischaemia has been the shift from bypass surgery to less invasive endovascular procedures as first choice revascularisation interventions. In the initial reports of percutaneous transluminal angioplasty use for critical limb ischaemia patients, relatively poor rates of secondary patency were frequently observed but with satisfactory values of limb salvage. Recent investigations for infrapopliteal angioplasty have shown increasingly better results in patency and limb salvage.
The Fenestrated Anaconda custom AAA Stent Graft System (Vascutek) achieves high procedural success in short-necked abdominal and pararenal aortic aneurysms, according to results from UK and Dutch experiences presented at the VEITHsymposium in November.
Biotronik has announced the twelve-month results from the prospective, multicentre, single-arm 4EVER study, which demonstrates the efficacy and safety of the Pulsar self-expanding stent system in 120 superficial femoral artery (SFA) patients.
On 14 November, Biotronik announced the first US implant of their Pulsar-18 self expanding stent in the BIOFLEX-I investigational device exemption clinical trial. Carlos Mena, Yale University Medical Center, USA, performed the procedure.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos